Drug Discovery Services Market

Drug Discovery Services Market by Process (Target Selection, Validation, Hit-to-lead), Type (Chemistry, Biology), Drug Type (Small molecules, biologics), Therapeutic Area (Oncology, Neurology) End User (Pharma, Biotech) - Global Forecast to 2026

Report Code: PH 5682 Feb, 2022, by marketsandmarkets.com

[281 Pages Report] The global Drug discovery services market is projected to reach USD 31.4 billion by 2026 from USD 16.1 billion in 2021, at a CAGR of 14.3% during the forecast period of 2021 to 2026. Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increasing demand for outsourcing analytical testing services, initiatives for research on rare diseases and orphan drugs, and the high cost of in-house drug development are creating new revenue pockets in the drug discovery services market. On the other hand, stringent regulations governing drug discovery and animal usage are expected to restrain market growth to a certain extent. The shortage of skilled professionals poses a challenge for drug discovery service providers.

Drug Discovery Services Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 impact on the Drug Discovery Services Market

COVID-19 is an infectious disease caused by the recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 quickly moved from a regional crisis to a global pandemic. The COVID-19 pandemic has increased the burden on healthcare systems across the globe. According to the World Health Organization (WHO), there were 336,790,193 confirmed cases of COVID-19 and 5,560,718 deaths as of January 20, 2022. The highest number of deaths was in the Americas, followed by Europe and Southeast Asia.

With the WHO officially declaring the outbreak of COVID-19 a pandemic, a mix of established pharmaceutical and biopharmaceutical companies have scaled up R&D and manufacturing efforts to develop and distribute test kits, vaccines, and drugs against the SARS-CoV-2 virus. To expedite the R&D process, many pharmaceutical and biotechnology companies teamed up with CROs through long-term agreements, partnerships, and collaborations across the globe. CROs have also developed dedicated services for COVID-19 research. In 2020, many new service launches and agreements, partnerships, and collaborations with different pharmaceutical companies and academic institutes for the research & development of COVID-19 vaccines, drugs, and diagnostics were recorded across the globe. For instance, in May 2021, Eurofins Scientific SE (France) launched Adaptive immune response models to understand the immune consequences of SARS-CoV-2 and other infectious diseases for drug discovery. In June 2020, PPD added five new molecular, serology, and functional assays for COVID-19 vaccine and therapy development programs.

Additionally, in July 2020, Albany Molecular Research Inc. partnered with ViralClear Pharmaceuticals to support and undertake an investigation to research the potential of merimepodib to fight SARS-CoV-2. Such strategies provided growth opportunities for large and small CROs, and, as a result, these firms witnessed double-digit growth rates in 2020. Thus, the COVID-19 outbreak has been a catalyst for outsourcing the drug development processes and has positively impacted every aspect of the pharmaceutical contract research industry.

Global Drug discovery services Market Dynamics

DRIVER: Growing R&D expenditure in the Pharma and Biopharma companies

Most pharmaceutical, biopharmaceutical, and medical device companies invest heavily in developing novel drugs and devices. The pharmaceutical industry is R&D-intensive. Pharmaceutical companies invest in R&D to deliver high-quality and innovative products to the market. Trends suggest that the top pharma companies are increasing their R&D efficiencies through heavy R&D investments to see returns in the longer term and through collaborative R&D efforts. According to the EvaluatePharma report, worldwide pharmaceutical R&D spending was valued at USD 137 billion in 2012; this increased to USD 198 billion in 2020. As a result of the COVID-19 outbreak, the global pharma R&D growth rate dropped to 0.1% in 2020. According to the report, this R&D spend is expected to grow steadily between 2020 and 2026 at a CAGR of 4.2% to reach USD 254.0 billion, slower than the historical CAGR of 4.7% between 2012 and 2020.

The rising R&D expenditure of pharmaceutical and biopharmaceutical companies is prompting them to opt for fully integrated or functional outsourcing services, from the early development stage to the late-stage development phase, for drug discovery and development. As there is enormous pressure on pharma companies to contain fixed costs, outsourcing has evolved as a strategic alternative to overcome the lack of in-house resources required for new product development. Big pharma companies are transitioning to a leaner business model that relies heavily on outsourcing. Most pharmaceutical and biopharmaceutical companies outsource their testing functions during R&D to improve profitability, meet the timelines involved in drug development, and save costs. This is evident from the recent agreements by major pharmaceutical companies with CROs providing drug discovery and development services. Thus, increasing pharmaceutical R&D expenditure supports the growth of the drug discovery services market.

RESTRAINT: Stringent regulations governing drug discovery and animal usage

Securing safety and efficacy is the prime focus of regulatory authorities during drug approval. Although these approaches help ensure the quality of the products launched in the market, they substantially increase the cost of drug development and the final product. In price-sensitive emerging markets, this factor can significantly impact the uptake of a particular drug. Apart from this, various legislations that ensure the quality of the product (such as GMP) often increase manufacturing costs.

Stringent guidelines govern the usage of animals in drug discovery. Mice, rats, fish, amphibians, and reptiles are the commonly used animals in any research. Concerns regarding the ethical use of animals in research have driven governments to introduce legislation for animal safety and use, which presents several challenges to the smooth functioning of drug discovery research. This has forced companies to implement other techniques to minimize animal use. For example, Novo Nordisk uses biosimulation, which involves using computer models to simulate human biology. However, this has not been fully adopted across the industry.

OPPORTUNITY: Growth in drugs and biologics market despite Covid-19 Pandemic

Despite the ongoing COVID-19 pandemic, 2020 has been the second-best year for the pharmaceutical industry regarding the number of drugs approved by the US FDA. This year witnessed the authorization of 53 drugs—a number surpassed only in 2018 with 59 pharmaceutical agents. The 53 approvals in 2020 comprised 40 new chemical entities and 13 biologics (of which ten were monoclonal antibodies, two were antibody-drug conjugates, three were peptides, and two, oligonucleotides). The FDA authorized 160 drugs in the last three years (2018–2020), compared to the approval of only 21 drugs in 2010.

This growth in the number of approved products worldwide is attributed to the rising investments by biopharmaceutical companies to develop biologics and biosimilars. More than half of the drug candidates in the discovery stage are biologics, such as proteins, peptides, and monoclonal antibodies. Biologics are expected to contribute around half of the revenue generated by the top 100 pharmaceutical product sales in 2022.

Although small-molecule drugs dominate the global pharmaceutical market, the share of biologics, biosimilars, and large-molecule drugs is growing, led by the launch of new biologic-based drugs and increased revenues from existing biologics. Biologics and biosimilars require more specialty testing services at each stage than small molecules. The increasing need for outsourcing these services to CROs is expected to stimulate the growth of the drug discovery services market in the coming years

CHALLENGE: Shortage of Skilled Personnel

The global pharmaceutical, biotechnology, and medical device R&D outsourcing industry is constantly evolving. Professionals must keep pace with the continuing changes in pharmaceutical R&D technologies and methodologies, provide quality services, and comply with good laboratory practices. CROs face challenges in attracting and retaining highly skilled professionals as they compete with pharmaceutical and biotechnology companies and academic and research institutions for qualified and experienced scientists.
To compete effectively, companies have to offer higher compensations and other benefits; this may affect the finances and results of operations of players, especially small-scale analytical testing providers. This shortage of skilled professionals may hamper the adoption of new technologies and methodologies and inhibit the growth of the drug discovery services market in the coming years.

The Chemistry segment dominated Drug discovery Market in 2020

Based on type, the drug discovery services market is broadly segmented into chemistry services and biology services. The chemistry services segment commanded the largest share of this market in 2020. Growth in this market segment is largely due to the widespread application of chemistry in various early drug development phases to deliver robust candidates.

Drug Discovery Services Market by Region

To know about the assumptions considered for the study, download the pdf brochure

North America was the largest regional market for Drug discovery services Market in 2020.

The global drug discovery services market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest regional market for drug discovery services with an estimated share of in 2020. This can be attributed to the presence of well-established CROs, rising R&D expenditure by pharmaceutical & biopharmaceutical companies, rapid growth in the biosimilar and biologics markets, and the availability of the latest techniques, instruments, and facilities for drug discovery research in the region.  

Key Market Players

Key players in the Drug discovery service Market include Laboratory Corporation of America Holdings (US), Charles River Laboratories International Inc. (US), WuXi AppTec (China), and Thermo Fisher Scientific Inc (US).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2019–2026

Base year considered

2020

Forecast period

2021–2026

Forecast units

Value (USD)

Segments covered

Process, Type, Drug Type, Therapeutic Area, End user and Region

Geographies covered

North America, Europe, Asia Pacific, Latin America (LATAM) and Middle East and Africa (MEA)

Companies covered

Laboratory Corporation of America Holdings (US), Eurofins Scientific SE (Germany), Charles River Laboratories International, Inc. (US), Evotec SE (Germany), WuXi AppTec (China), Pharmaceutical Product Development LLC (US), Syngene International Limited (India), Curia Global Inc. (US), Dr. Reddy Laboratories Ltd. (Aurigene Discovery Technologies) (India), Pharmaron Beijing Co., Ltd. (China), Piramal Enterprises Limited (India), Thermo Fisher Scientific Inc. (US), Jubilant Pharmova Limited (India), GenScript Biotech Corporation (US), Selvita S.A. (Poland), Shanghai Medicilon Inc. (China), Viva Biotech (Shanghai) Ltd. (China), TCG Lifesciences Pvt Ltd. (India), Shanghai ChemPartner Co., Ltd. (China), Domainex Ltd. (UK), NUVISAN Pharma Holding GmbH (Germany), Frontage Holdings Corporation (US), Dalton Pharma Services (Canada), Aragen Life Sciences Pvt. Ltd. (India), and Promega Corporation (US).

This report categorizes the drug discovery services market into the following segments and subsegments:

Drug Discovery Market, by Process

  • Target Selection
  • Target Validation
  • Hit-to-Lead identification
  • Lead Optimization
  • Candidate Validation

Drug Discovery Services Market, by Type

  • Chemistry Services
  • Biology Services

Drug Discovery Services Market, by Drug Type

  • Small-molecule drugs
  • Biologics drugs
  • Drug Discovery Services Market, by Therapeutic Area
  • Oncology
  • Infectious and Immune system diseases
  • Neurology
  • Digestive system diseases
  • Cardiovascular diseases
  • Other Therapeutic Area (metabolic disorders/endocrinology, respiratory disorders, psychiatry, dermatology, ophthalmology, genitourinary, women’s health, and orphan and rare diseases)

Drug Discovery Services Market, by End user

  • Pharmaceutical & Biotechnology companies
  • Academic Institutes
  • Other End Users (small CROs, IVD companies, and clinical laboratories)

Drug Discovery services Market, by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia Pacific (RoAPAC)
  • Latin America (LATAM)
    • Brazil
    • RoLATAM
  • Middle East and Africa (MEA)

Recent Developments

  • In December 2021, Curia (US) launched messenger RNA (mRNA) solution, which includes discovery, process development, and mRNA drug substance production, through large-scale lipid manufacturing, lipid nanoparticle (LNP) formulation, and development for full-scale sterile fill-finish services.
  • In September 2021, Eurofins collaborated with Liverpool ChiroChem Ltd to provide enhanced chemical expertise by accessing LCC’s fragment library and PROTAC linker molecules to augment their integrated drug discovery platform, DiscoveryOne.

Frequently Asked Questions FAQs:

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 26)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 30)
    2.1 RESEARCH DATA
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
    2.2 MARKET ESTIMATION METHODOLOGY
           2.2.1 INSIGHTS FROM PRIMARY EXPERTS
    2.3 MARKET GROWTH RATE PROJECTIONS
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    2.5 RESEARCH ASSUMPTIONS
    2.6 COVID-19 SPECIFIC ASSUMPTIONS
    2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 42)

4 PREMIUM INSIGHTS (Page No. - 46)
    4.1 DRUG DISCOVERY SERVICES MARKET OVERVIEW
    4.2 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE AND COUNTRY (2020)
    4.3 DRUG DISCOVERY SERVICES MARKET SHARE, BY TYPE (2020)
    4.4 DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    4.5 DRUG DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW (Page No. - 50)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           5.2.1 DRIVERS
                    5.2.1.1 Growing R&D expenditure in the pharma & biopharma industry
                    5.2.1.2 Increasing demand for outsourcing analytical testing
                    5.2.1.3 Initiatives for research on rare diseases and orphan drugs
                    5.2.1.4 High cost of in-house drug development
           5.2.2 RESTRAINTS
                    5.2.2.1 Stringent regulations governing drug discovery and animal usage
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growth in drugs and biologics market despite COVID-19 pandemic
                    5.2.3.2 Rising demand for specialized testing services among end users
                    5.2.3.3 Patent expiry
                    5.2.3.4 High growth prospects in emerging markets
           5.2.4 CHALLENGES
                    5.2.4.1 Shortage of skilled personnel
           5.2.5 MARKET TRENDS
                    5.2.5.1 Shift in drug discovery services due to growing adoption of AI-based tools
                    5.2.5.2 Increased outsourcing to emerging Asian economies
                    5.2.5.3 CRO industry consolidation
                    5.2.5.4 Integrated end-to-end R&D service solution
    5.3 IMPACT OF COVID-19 ON THE DRUG DISCOVERY SERVICES MARKET
           5.3.1 ASSUMPTIONS – DRUG DISCOVERY SERVICES MARKET ESTIMATION AND FORECAST
           5.3.2 ASSUMPTIONS – COMPANY REVENUE GROWTH
    5.4 RANGES/SCENARIO
    5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
    5.6 VALUE CHAIN ANALYSIS
    5.7 ECOSYSTEM ANALYSIS
    5.8 TECHNOLOGY ANALYSIS
    5.9 REGULATORY ANALYSIS
    5.10 PORTER’S FIVE FORCES ANALYSIS
           5.10.1 THREAT OF NEW ENTRANTS
           5.10.2 THREAT OF SUBSTITUTES
           5.10.3 BARGAINING POWER OF BUYERS
           5.10.4 BARGAINING POWER OF SUPPLIERS
           5.10.5 DEGREE OF COMPETITION

6 DRUG DISCOVERY SERVICES MARKET, BY PROCESS (Page No. - 74)
    6.1 INTRODUCTION
    6.2 TARGET SELECTION
           6.2.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE TO SUPPORT THE GROWTH OF THIS MARKET
    6.3 TARGET VALIDATION
           6.3.1 RISING NUMBER OF DRUG DISCOVERY RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH
    6.4 HIT-TO-LEAD IDENTIFICATION
           6.4.1 HIT-TO-LEAD IDENTIFICATION IS THE LARGEST PROCESS SEGMENT IN THE MARKET
    6.5 LEAD OPTIMIZATION
           6.5.1 LEAD OPTIMIZATION REQUIRES STATE-OF-THE-ART INFORMATICS SYSTEMS TO FACILITATE TRANSPARENT PRESENTATION AND ANALYSIS
    6.6 CANDIDATE VALIDATION
           6.6.1 FUTURE MANUFACTURING SUITABILITY, SCALE-UP, COMMERCIAL VIABILITY, AND COST-EFFECTIVENESS OF CANDIDATES HEAVILY IMPACT THE LONG-TERM SUCCESS OF DRUGS

7 DRUG DISCOVERY SERVICES MARKET, BY TYPE (Page No. - 88)
    7.1 INTRODUCTION
    7.2 CHEMISTRY SERVICES
           7.2.1 GROWING CHEMICAL & BIOCHEMICAL TESTS AND WIDE APPLICATIONS OF CHEMISTRY IN DRUG DISCOVERY ARE MAJOR FACTORS DRIVING MARKET GROWTH
    7.3 BIOLOGY SERVICES
           7.3.1 THE INTRODUCTION OF GENOMICS AND PROTEOMICS WILL ENHANCE MARKET GROWTH

8 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE (Page No. - 94)
    8.1 INTRODUCTION
    8.2 SMALL-MOLECULE DRUGS
           8.2.1 INCREASING NUMBER OF START-UPS AND NEW ENTRANTS IN THE SMALL-MOLECULE DRUGS SEGMENT WILL DRIVE THE GROWTH OF THIS MARKET
    8.3 BIOLOGIC DRUGS
           8.3.1 SAFETY AND MANUFACTURING CHALLENGES ASSOCIATED WITH BIOLOGICS DEVELOPMENT TO DRIVE ADOPTION OF OUTSOURCING SERVICES

9 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA (Page No. - 101)
    9.1 INTRODUCTION
    9.2 ONCOLOGY
           9.2.1 HIGH AND GROWING NUMBER OF RESEARCH STUDIES ON CANCER THERAPEUTICS TO SUPPORT MARKET GROWTH
    9.3 INFECTIOUS & IMMUNE SYSTEM DISEASES
           9.3.1 EPIDEMIC OUTBREAKS NECESSITATE INCREASING DRUG DISCOVERY ACTIVITIES
    9.4 NEUROLOGY
           9.4.1 THE INCREASING NUMBER OF PATIENTS SUFFERING FROM NEUROLOGICAL DISORDERS IS DRIVING MARKET GROWTH
    9.5 DIGESTIVE SYSTEM DISEASES
           9.5.1 LARGE POPULATION SEEKING EFFECTIVE REMEDIES FOR DIGESTIVE DISEASES IS EXPECTED TO DRIVE THE MARKET
    9.6 CARDIOVASCULAR DISEASES
           9.6.1 THE HIGH GLOBAL BURDEN OF CARDIOVASCULAR DISEASES HAS INCREASED THE FOCUS ON DEVELOPING EFFECTIVE DRUGS
    9.7 OTHER THERAPEUTIC AREAS

10 DRUG DISCOVERY SERVICES MARKET, BY END USER (Page No. - 119)
     10.1 INTRODUCTION
     10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
             10.2.1 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE
             10.2.2 TIER 1 COMPANIES
                        10.2.2.1 High investing capacity is the major factor driving the growth of this segment
             10.2.3 TIER 2 COMPANIES
                        10.2.3.1 Limited investment capacity is expected to restrain the growth of this segment
             10.2.4 TIER 3 COMPANIES
                        10.2.4.1 Tier 3 companies are smaller and have fewer technical advantages
     10.3 ACADEMIC INSTITUTES
             10.3.1 COLLABORATION WITH MARKET PLAYERS TO PROVIDE MORE FLEXIBLE AND EFFICIENT PATHWAYS FOR CLINICAL DEVELOPMENT
     10.4 OTHER END USERS

11 DRUG DISCOVERY SERVICES MARKET, BY REGION (Page No. - 131)
     11.1 INTRODUCTION
     11.2 NORTH AMERICA
             11.2.1 US
                        11.2.1.1 Availability of advanced R&D infrastructure has driven the growth of the US market
             11.2.2 CANADA
                        11.2.2.1 Preference of pharmaceutical companies to conduct clinical trials in Canada to support market growth
     11.3 EUROPE
             11.3.1 GERMANY
                        11.3.1.1 Government support and flexible labor laws are driving the growth of the German drug discovery services market
             11.3.2 UK
                        11.3.2.1 Collaborations between the government and private stakeholders to support market growth
             11.3.3 FRANCE
                        11.3.3.1 The high number of oncology research projects in France to drive market growth
             11.3.4 ITALY
                        11.3.4.1 High number of clinical trials and the low drug approval time are the major factors driving market growth
             11.3.5 SPAIN
                        11.3.5.1 Short study start-up times and rising R&D expenditure to boost the growth of the Spanish market
             11.3.6 REST OF EUROPE
     11.4 ASIA PACIFIC
             11.4.1 CHINA
                        11.4.1.1 China dominates the Asia Pacific market due to a robust pharmaceutical industry and the presence of prominent CROs
             11.4.2 JAPAN
                        11.4.2.1 Government initiatives for drug innovation to support market growth in Japan
             11.4.3 INDIA
                        11.4.3.1 Low-cost services and availability of skilled workforce and strong government support to drive market growth in India
             11.4.4 SOUTH KOREA
                        11.4.4.1 Government initiatives and growing R&D activities for drug development to drive market growth
             11.4.5 REST OF ASIA PACIFIC
     11.5 LATIN AMERICA
             11.5.1 BRAZIL
                        11.5.1.1 The presence of a large pool of treatment-naοve patients and short approval timeline is expected to drive market growth in this region
             11.5.2 REST OF LATIN AMERICA
     11.6 MIDDLE EAST & AFRICA
             11.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH IN THE MIDDLE EAST AND AFRICA

12 COMPETITIVE LANDSCAPE (Page No. - 183)
     12.1 OVERVIEW
     12.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN
     12.3 MARKET SHARE ANALYSIS
     12.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
     12.5 COMPANY EVALUATION QUADRANT
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
     12.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 STARTING BLOCKS
             12.6.3 RESPONSIVE COMPANIES
             12.6.4 DYNAMIC COMPANIES
     12.7 COMPANY SERVICE FOOTPRINT
     12.8 COMPANY GEOGRAPHIC FOOTPRINT
     12.9 COMPETITIVE SCENARIO
             12.9.1 SERVICE LAUNCHES
             12.9.2 DEALS
             12.9.3 EXPANSION

13 COMPANY PROFILES (Page No. - 196)
     13.1 KEY PLAYERS
             13.1.1 LABORATORY CORPORATION OF AMERICA HOLDINGS
                        13.1.1.1 Business overview
                        13.1.1.2 Services offered
                        13.1.1.3 Recent developments
                        13.1.1.4 MnM view
                                     13.1.1.4.1 Key strengths/Right to win
                                     13.1.1.4.2 Strategic choices made
                                     13.1.1.4.3 Weaknesses and competitive threats
             13.1.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
                        13.1.2.1 Business overview
                        13.1.2.2 Services offered
                        13.1.2.3 Recent developments
                        13.1.2.4 MnM view
                                     13.1.2.4.1 Key strengths/Right to win
                                     13.1.2.4.2 Strategic choices made
                                     13.1.2.4.3 Weaknesses and competitive threats
             13.1.3 WUXI APPTEC
                        13.1.3.1 Business overview
                        13.1.3.2 Services offered
                        13.1.3.3 Recent developments
                        13.1.3.4 MnM view
                                     13.1.3.4.1 Key strengths/Right to win
                                     13.1.3.4.2 Strategic choices made
                                     13.1.3.4.3 Weaknesses and competitive threats
             13.1.4 THERMO FISHER SCIENTIFIC
                        13.1.4.1 Business overview
                        13.1.4.2 Services offered
                        13.1.4.3 Recent developments
             13.1.5 PHARMARON BEIJING CO., LTD.
                        13.1.5.1 Business overview
                        13.1.5.2 Services offered
                        13.1.5.3 Recent developments
             13.1.6 EVOTEC SE
                        13.1.6.1 Business overview
                        13.1.6.2 Services offered
                        13.1.6.3 Recent developments
             13.1.7 EUROFINS SCIENTIFIC SE
                        13.1.7.1 Business overview
                        13.1.7.2 Services offered
                        13.1.7.3 Recent developments
             13.1.8 PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
                        13.1.8.1 Business overview
                        13.1.8.2 Services offered
             13.1.9 PIRAMAL ENTERPRISES LIMITED
                        13.1.9.1 Business overview
                        13.1.9.2 Services offered
                        13.1.9.3 Recent developments
             13.1.10 SYNGENE INTERNATIONAL LIMITED
                        13.1.10.1 Business overview
                        13.1.10.2 Services offered
                        13.1.10.3 Recent developments
             13.1.11 CURIA GLOBAL INC.
                        13.1.11.1 Business overview
                        13.1.11.2 Services offered
                        13.1.11.3 Recent developments
             13.1.12 GENSCRIPT BIOTECH CORPORATION
                        13.1.12.1 Business overview
                        13.1.12.2 Services offered
                        13.1.12.3 Recent developments
             13.1.13 JUBILANT PHARMOVA LIMITED
                        13.1.13.1 Business overview
                        13.1.13.2 Services offered
                        13.1.13.3 Recent developments
             13.1.14 FRONTAGE HOLDINGS CORPORATION
                        13.1.14.1 Business overview
                        13.1.14.2 Services offered
                        13.1.14.3 Recent developments
             13.1.15 SHANGHAI MEDICILON INC.
                        13.1.15.1 Business overview
                        13.1.15.2 Services offered
                        13.1.15.3 Recent developments
             13.1.16 DR. REDDY’S LABORATORIES LTD. (AURIGENE DISCOVERY TECHNOLOGIES)
                        13.1.16.1 Business overview
                        13.1.16.2 Services offered
                        13.1.16.3 Recent developments
     13.2 OTHER COMPANIES
             13.2.1 SELVITA S.A. (FORMERLY SELVITA CRO S.A.)
             13.2.2 VIVA BIOTECH (SHANGHAI) LTD.
             13.2.3 TCG LIFESCIENCES PVT LTD.
             13.2.4 SHANGHAI CHEMPARTNER CO., LTD.
             13.2.5 DOMAINEX LTD.
             13.2.6 NUVISAN PHARMA HOLDING GMBH
             13.2.7 DALTON PHARMA SERVICES
             13.2.8 ARAGEN LIFE SCIENCES PVT. LTD. (FORMERLY GVK BIOSCIENCES PVT. LTD.)
             13.2.9 PROMEGA CORPORATION

14 APPENDIX (Page No. - 274)
     14.1 DISCUSSION GUIDE
     14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     14.3 AVAILABLE CUSTOMIZATIONS
     14.4 RELATED REPORT
     14.5 AUTHOR DETAILS


LIST OF TABLES (249 Tables)

TABLE 1 DRUG DISCOVERY AND DEVELOPMENT PROCESS OVERVIEW
TABLE 2 DRUG DISCOVERY SERVICES MARKET: IMPACT ANALYSIS
TABLE 3 LIST OF BIOLOGICS APPROVALS BY US FDA, 2020
TABLE 4 US: BIOLOGICS GOING OFF-PATENT DURING 2018–2025
TABLE 5 LIST OF ACQUISITIONS
TABLE 6 SUPPLY CHAIN ECOSYSTEM
TABLE 7 REGULATORY SCENARIO
TABLE 8 DRUG DISCOVERY SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 9 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019–2026 (USD MILLION)
TABLE 10 DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY REGION, 2019–2026 (USD MILLION)
TABLE 11 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 12 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 13 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 14 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 15 DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 2019–2026 (USD MILLION)
TABLE 16 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 17 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 18 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 19 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 20 DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2019–2026 (USD MILLION)
TABLE 21 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 22 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 23 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 24 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 25 DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2019–2026 (USD MILLION)
TABLE 26 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 27 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 28 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 29 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 30 DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2019–2026 (USD MILLION)
TABLE 31 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 32 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 33 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 34 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 35 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 36 CHEMISTRY SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 37 NORTH AMERICA: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 38 EUROPE: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 39 APAC: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 40 LATIN AMERICA: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 41 BIOLOGY SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 42 NORTH AMERICA: BIOLOGY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 43 EUROPE: BIOLOGY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 44 APAC: BIOLOGY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 45 LATIN AMERICA: BIOLOGY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 46 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019–2026 (USD MILLION)
TABLE 47 DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 2019–2026 (USD MILLION)
TABLE 48 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 49 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 50 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 51 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 52 DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS, BY REGION, 2019–2026 (USD MILLION)
TABLE 53 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 54 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS DRUG, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 55 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 56 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 57 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 58 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2020)
TABLE 59 ONCOLOGY DRUG DISCOVERY SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 60 ONCOLOGY DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 61 EUROPE: ONCOLOGY DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 62 ASIA PACIFIC: ONCOLOGY DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 63 LATIN AMERICA: ONCOLOGY DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 64 INFECTIOUS & IMMUNE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 65 NORTH AMERICA: INFECTIOUS & IMMUNE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 66 EUROPE: INFECTIOUS & IMMUNE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 67 ASIA PACIFIC: INFECTIOUS & IMMUNE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 68 LATIN AMERICA: INFECTIOUS & IMMUNE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 69 MEDICINES IN DEVELOPMENT FOR NEUROGENERATIVE DISEASES (2021)
TABLE 70 NEUROLOGY DRUG DISCOVERY SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 71 NORTH AMERICA: NEUROLOGY DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 72 EUROPE: NEUROLOGY DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 73 ASIA PACIFIC: NEUROLOGY DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 74 LATIN AMERICA: NEUROLOGY DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 75 DIGESTIVE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 76 NORTH AMERICA: DIGESTIVE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 77 EUROPE: DIGESTIVE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 78 ASIA PACIFIC: DIGESTIVE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 79 LATIN AMERICA: DIGESTIVE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 80 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2020)
TABLE 81 CARDIOVASCULAR DISEASE DRUG DISCOVERY SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 82 NORTH AMERICA: CARDIOVASCULAR DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 83 EUROPE: CARDIOVASCULAR DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 84 ASIA PACIFIC: CARDIOVASCULAR DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 85 LATIN AMERICA: CARDIOVASCULAR DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 86 DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2019–2026 (USD MILLION)
TABLE 87 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 88 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 89 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 90 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 91 DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 92 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 93 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 94 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 95 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 96 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 97 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 98 TOP PHARMA COMPANIES BY 2020 REVENUE
TABLE 99 DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 100 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 101 DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 102 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 103 DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 104 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 105 DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2019–2026 (USD MILLION)
TABLE 106 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 107 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 108 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 109 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 110 DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION)
TABLE 111 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 112 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 113 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 114 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 115 DRUG DISCOVERY SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 116 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 117 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019–2026 (USD MILLION)
TABLE 118 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 119 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019–2026 (USD MILLION)
TABLE 120 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 121 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 122 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 123 US: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019–2026 (USD MILLION)
TABLE 124 US: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 125 US: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019–2026 (USD MILLION)
TABLE 126 US: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 127 US: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 128 US: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 129 CANADA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019–2026 (USD MILLION)
TABLE 130 CANADA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 131 CANADA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019–2026 (USD MILLION)
TABLE 132 CANADA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 133 CANADA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 134 CANADA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 135 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 136 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019–2026 (USD MILLION)
TABLE 137 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 138 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019–2026 (USD MILLION)
TABLE 139 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 140 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 141 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 142 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019–2026 (USD MILLION)
TABLE 143 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 144 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019–2026 (USD MILLION)
TABLE 145 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 146 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 147 UK: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019–2026 (USD MILLION)
TABLE 148 UK: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 149 UK: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019–2026 (USD MILLION)
TABLE 150 UK: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 151 UK: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 152 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019–2026 (USD MILLION)
TABLE 153 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 154 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019–2026 (USD MILLION)
TABLE 155 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 156 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 157 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY (JANUARY 2021)
TABLE 158 ITALY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019–2026 (USD MILLION)
TABLE 159 ITALY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 160 ITALY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019–2026 (USD MILLION)
TABLE 161 ITALY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 162 ITALY: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 163 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019–2026 (USD MILLION)
TABLE 164 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 165 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019–2026 (USD MILLION)
TABLE 166 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 167 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 168 ROE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019–2026 (USD MILLION)
TABLE 169 ROE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 170 ROE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019–2026 (USD MILLION)
TABLE 171 ROE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 172 ROE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 173 APAC: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 174 APAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019–2026 (USD MILLION)
TABLE 175 APAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 176 APAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019–2026 (USD MILLION)
TABLE 177 APAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 178 APAC: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 179 APAC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 180 CHINA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019–2026 (USD MILLION)
TABLE 181 CHINA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 182 CHINA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019–2026 (USD MILLION)
TABLE 183 CHINA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 184 CHINA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 185 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019–2026 (USD MILLION)
TABLE 186 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 187 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019–2026 (USD MILLION)
TABLE 188 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 189 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 190 INDIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019–2026 (USD MILLION)
TABLE 191 INDIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 192 INDIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019–2026 (USD MILLION)
TABLE 193 INDIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 194 INDIA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 195 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019–2026 (USD MILLION)
TABLE 196 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 197 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019–2026 (USD MILLION)
TABLE 198 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 199 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 200 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019–2026 (USD MILLION)
TABLE 201 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 202 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019–2026 (USD MILLION)
TABLE 203 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 204 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 205 LATAM: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 206 LATAM: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019–2026 (USD MILLION)
TABLE 207 LATAM: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 208 LATAM: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019–2026 (USD MILLION)
TABLE 209 LATAM: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 210 LATAM: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 211 LATAM: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 212 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019–2026 (USD MILLION)
TABLE 213 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 214 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019–2026 (USD MILLION)
TABLE 215 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 216 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 217 ROLATAM: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019–2026 (USD MILLION)
TABLE 218 ROLATAM: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 219 ROLATAM: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019–2026 (USD MILLION)
TABLE 220 ROLATAM: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 221 ROLATAM: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 222 MEA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019–2026 (USD MILLION)
TABLE 223 MEA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 224 MEA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019–2026 (USD MILLION)
TABLE 225 MEA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 226 MEA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 227 MEA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 228 DRUG DISCOVERY SERVICES MARKET: DEGREE OF COMPETITION
TABLE 229 PRODUCT PORTFOLIO ANALYSIS: DRUG DISCOVERY SERVICES MARKET (2020)
TABLE 230 GEOGRAPHIC REVENUE MIX: DRUG DISCOVERY SERVICES MARKET (2020)
TABLE 231 SERVICE LAUNCHES
TABLE 232 DEALS
TABLE 233 EXPANSION
TABLE 234 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW
TABLE 235 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW
TABLE 236 WUXI APPTEC: BUSINESS OVERVIEW
TABLE 237 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
TABLE 238 PHARMARON BEIJING CO., LTD.: BUSINESS OVERVIEW
TABLE 239 EVOTEC SE : BUSINESS OVERVIEW
TABLE 240 EUROFINS SCIENTIFIC SE: BUSINESS OVERVIEW
TABLE 241 PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.: BUSINESS OVERVIEW
TABLE 242 PIRAMAL ENTERPRISES LIMITED: BUSINESS OVERVIEW
TABLE 243 SYNGENE INTERNATIONAL LIMITED: BUSINESS OVERVIEW
TABLE 244 CURIA GLOBAL INC.: BUSINESS OVERVIEW
TABLE 245 GENSCRIPT BIOTECH CORPORATION: BUSINESS OVERVIEW
TABLE 246 JUBILANT PHARMOVA LIMITED: BUSINESS OVERVIEW
TABLE 247 FRONTAGE HOLDINGS CORPORATION: BUSINESS OVERVIEW
TABLE 248 SHANGHAI MEDICILON INC.: BUSINESS OVERVIEW
TABLE 249 DR. REDDY’S LABORATORIES LTD.: BUSINESS OVERVIEW

LIST OF FIGURES (54 Figures)

FIGURE 1 RESEARCH DESIGN
FIGURE 2 DRUG DISCOVERY SERVICES MARKET: BREAKDOWN OF PRIMARIES
FIGURE 3 DRUG DISCOVERY SERVICES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2020
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2020
FIGURE 5 ILLUSTRATIVE EXAMPLE OF COMPANY REVENUE ANALYSIS, 2020
FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 7 DRUG DISCOVERY SERVICES MARKET (SUPPLY-SIDE): CAGR PROJECTIONS
FIGURE 8 DRUG DISCOVERY SERVICES MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS
FIGURE 9 DATA TRIANGULATION METHODOLOGY
FIGURE 10 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 11 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021 VS. 2026 (USD MILLION)
FIGURE 12 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021 VS. 2026 (USD MILLION)
FIGURE 13 DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF THE DRUG DISCOVERY SERVICES MARKET
FIGURE 15 INCREASING R&D EXPENDITURE IN THE PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY WILL DRIVE MARKET GROWTH
FIGURE 16 SMALL-MOLECULE DRUGS ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN DRUG DISCOVERY MARKET IN 2020
FIGURE 17 CHEMISTRY SERVICES SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2020
FIGURE 18 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES WILL CONTINUE TO DOMINATE THE MARKET IN 2026
FIGURE 19 ASIA PACIFIC COUNTRIES TO REGISTER THE HIGHEST GROWTH IN THE DRUG DISCOVERY SERVICES MARKET FROM 2021 TO 2026
FIGURE 20 DRUG DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 21 RISING GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026
FIGURE 22 ACTIVE PHARMACEUTICAL PIPELINE, 2011–2021
FIGURE 23 NUMBER OF ORPHAN INDICATIONS APPROVED IN THE US (2010–2019)
FIGURE 24 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010–2020 (USD BILLION)
FIGURE 25 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (2001–2020)
FIGURE 26 DRUG DISCOVERY SERVICES MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2019–2026
FIGURE 27 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON GROWTH OF THE DRUG DISCOVERY SERVICES MARKET
FIGURE 28 REVENUE SHIFT & NEW POCKETS FOR DRUG DISCOVERY SERVICE PROVIDERS
FIGURE 29 VALUE CHAIN ANALYSIS OF DRUG DISCOVERY SERVICES MARKET: HIT-TO-LEAD IDENTIFICATION AND LEAD OPTIMIZATION PHASES ADD MAXIMUM VALUE 66
FIGURE 30 ECOSYSTEM ANALYSIS: DRUG DISCOVERY SERVICES MARKET
FIGURE 31 INCIDENCE OF MAJOR TYPES OF CANCER CASES WORLDWIDE (2020)
FIGURE 32 PHRMA MEMBER COMPANY R&D EXPENDITURE, 2017–2020 (USD BILLION)
FIGURE 33 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET SNAPSHOT
FIGURE 34 US CONTINUES TO DOMINATE THE DISTRIBUTION OF R&D COMPANIES BY REGION (2019 VS. 2020)
FIGURE 35 APAC: DRUG DISCOVERY SERVICES MARKET SNAPSHOT
FIGURE 36 KEY PLAYERS STRATEGIES IN THE DRUG DISCOVERY SERVICES MARKET, 2019–2021
FIGURE 37 DRUG DISCOVERY SERVICES MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
FIGURE 38 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN THE DRUG DISCOVERY MARKET, 2018-2020
FIGURE 39 DRUG DISCOVERY SERVICES MARKET: COMPANY EVALUATION QUADRANT, 2020
FIGURE 40 DRUG DISCOVERY SERVICES MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
FIGURE 41 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2020)
FIGURE 42 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2020)
FIGURE 43 WUXI APPTEC: COMPANY SNAPSHOT (2020)
FIGURE 44 THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT (2020)
FIGURE 45 PHARMARON BEIJING CO., LTD.: COMPANY SNAPSHOT (2020)
FIGURE 46 EVOTEC SE: COMPANY SNAPSHOT (2020)
FIGURE 47 EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT (2020)
FIGURE 48 PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.: COMPANY SNAPSHOT (2020)
FIGURE 49 PIRAMAL ENTERPRISES LIMITED: COMPANY SNAPSHOT (2020)
FIGURE 50 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT (2020)
FIGURE 51 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2020)
FIGURE 52 JUBILANT PHARMOVA LIMITED: COMPANY SNAPSHOT (2020)
FIGURE 53 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT (2020)
FIGURE 54 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2020)

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global drug discovery services market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

The secondary sources referred to for this research study include publications from government sources, such as Association of International Contract Research Organizations (AICROS), American Association of Pharmaceutical Scientists (AAPS), Clinical and Contract Research Association (CCRA), Association of Clinical Research Organizations (ACRO), Clinical Research Society (CRS), Pharmaceutical Research and Manufacturers of America (PhRMA), National Center for Biotechnology Information (NCBI), Food and Drug Administration (FDA). Secondary sources also include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global drug discovery services market, which was validated through primary research.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global drug discovery services market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as personnel from pharmaceutical and biopharmaceutical industries, CDMOs and CROs, academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across four major regions, including North America, Europe, the Asia Pacific, and the Rest of the World. Approximately 70% and 30% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

 The following is a breakdown of the primary respondents:

Drug Discovery Services Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the drug discovery services market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the drug discovery services market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive primary and secondary research.
  • The revenues generated from the drug discovery services business of leading players have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.   

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Objectives

  • To define, describe, and forecast the drug discovery services market by type, drug type, process, end user, and region
  • To provide detailed information about the major factors influencing the market growth (drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to the individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments in North America, Europe, Asia Pacific,  Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their market shares and core competencies in the global drug discovery services market
  • To track and analyze competitive developments such as product & service launches, partnerships, collaborations, agreements, expansions, and acquisitions in the global drug discovery services market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Geographical Analysis

  • Further breakdown of the RoE drug discovery services market, by country
  • Further breakdown of the RoAPAC drug discovery services market, by country
  • Further breakdown of the RoLA and MEA drug discovery services markets, by country

Company Information

  • Detailed analysis and profiling of additional market players (Up to five)

Segment Analysis

  • Further breakdown of the therapeutic area segment as per the service portfolio of prominent players operating in the market.  
Report Code
PH 5682
Published ON
Feb, 2022
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Drug Discovery Services Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback